Vanguard Group Inc Pro Phase Labs, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 408,267 shares of PRPH stock, worth $142,893. This represents 0.0% of its overall portfolio holdings.
Number of Shares
408,267
Previous 408,267
-0.0%
Holding current value
$142,893
Previous $163,000
2.45%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding PRPH
# of Institutions
34Shares Held
2.68MCall Options Held
12.3KPut Options Held
0-
Sykon Capital LLC Harrison, NY645KShares$225,6780.09% of portfolio
-
Geode Capital Management, LLC Boston, MA259KShares$90,6720.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL229KShares$80,3080.0% of portfolio
-
Quinn Opportunity Partners LLC Charlottesville, VA218KShares$76,3440.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny138KShares$48,2730.0% of portfolio
About ProPhase Labs, Inc.
- Ticker PRPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 16,024,400
- Market Cap $5.61M
- Description
- ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...